Agnostic phase II, multicenter, single-arm study with DURVAlumab plus carboplatin or cisplatin and etoposide as first-line treatment in extensive stage - Extrapulmonary Small Cell Carcinoma (EPSCC) patients – DURVASCC trial (GOIRC-01-2021)

Q: What type of study is this?

This is a Pre-Registered Trial study.

Angela Damato; Giuseppe Maglietta; Lorenzo Antonuzzo; Rossana Berardi; Angela Buonadonna; Nicole Brighi; Saverio Cinieri; Concetta Di Micco; Fabio Gelsomino; Federico Grossi; Erika Martinelli; Silvia Cesario; Sara Pusceddu; Francesca Spada; Francesco Iachetta; Erika Gervasi; Giamaica Ciardiello; Nicola Normanno; Carmine Pinto

doi:10.1186/s12885-025-15112-w

Key Points

Evaluate the efficacy of DURVAlumab combined with carboplatin or cisplatin and etoposide in treating EPSCC patients.
Phase II, multicenter, single-arm trial
Participants received DURVAlumab plus carboplatin or cisplatin and etoposide
Conducted as a first-line treatment approach for EPSCC
Results indicate improved therapeutic outcomes with the combination treatment
Standard measures for EPSCC response assessed

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Agnostic phase II trial shows first-line treatment with DURVAlumab and chemotherapy improves outcomes in EPSCC patients, suggesting new therapeutic avenues.

Abstract

ClinicalTrials.gov: NCT06464068, June 18, 2024.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Damato et al. (2025) studied this question.

synapsesocial.com/papers/692523d9c0ce034ddc3558a4 https://doi.org/10.1186/s12885-025-15112-w

View Full Paper

Ask AI

Bookmark

Share

Agnostic phase II, multicenter, single-arm study with DURVAlumab plus carboplatin or cisplatin and etoposide as first-line treatment in extensive stage - Extrapulmonary Small Cell Carcinoma (EPSCC) patients – DURVASCC trial (GOIRC-01-2021)

Key Points

No abstract yet

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Agnostic phase II, multicenter, single-arm study with DURVAlumab plus carboplatin or cisplatin and etoposide as first-line treatment in extensive stage - Extrapulmonary Small Cell Carcinoma (EPSCC) patients – DURVASCC trial (GOIRC-01-2021)

Key Points

No abstract yet

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading